Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359097 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL28397725 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL3760910 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL14748299 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL19585105 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL3137028 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL2246998 | 0.83 | TSHR (0.45) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL2251994 | 0.83 | TSHR (0.45) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL25787135 | 0.83 | TP53 (0.43) | TSHRTP53SLC7A5CYP2C9FPR1 | |
| Butyric Acid SCHEMBL16972049 | 0.82 | FFAR3 (0.52) | TSHRPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 813 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606850-B2 | Synthesis of beta-hydroxyisovalerate and methods of use | Sasya, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20250313852-A1 | BIDIRECTIONAL CHEF1 VECTORS | AGC BIOLOGICS INC (US) | 2025-10-09 | — | — | US | claimed |
| EP-3957736-B1 | PRODUCTION OF ODD CHAIN FATTY ACID DERIVATIVES IN RECOMBINANT MICROBIAL CELLS | GENOMATICA INC (US) | 2025-08-06 | — | — | EP | claimed |
| CN-119752907-A | Promoter mutant and application thereof | 安徽华恒生物科技股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119709813-A | Shuttle vector system based on blue algae endogenous plasmid | 厦门大学 | 2025-03-28 | — | — | CN | claimed |
| US-12234495-B2 | Synthesis of beta-hydroxyisovalerate and methods of use | Sasya Inc. (US) | 2025-02-25 | — | — | US | claimed |
| US-20250002949-A1 | SYNTHESIS OF BETA-HYDROXYISOVALERATE AND METHODS OF USE | Sasya Inc. | 2025-01-02 | — | — | US | claimed |
| CN-117757705-A | Construction and application of genetic engineering strain capable of realizing co-production of branched-chain amino acid | 元素驱动(杭州)生物科技有限公司 | 2024-03-26 | — | — | CN | claimed |
| US-11920177-B2 | Synthesis of beta-hydroxyisovalerate and methods of use | Sasya Inc. (US) | 2024-03-05 | — | — | US | claimed |
| WO-2008098227-A2 | BIOFUEL PRODUCTION BY RECOMBINANT MICROORGANISMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-14 | — | — | WO | claimed |
| WO-2008078911-A1 | METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-07-03 | — | — | WO | claimed |
| EP-1461460-A4 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ASPARAGINE SYNTHASE, 5-AMINOLEVULINATE SYNTHASE, HISTIDINOL-PHOSPHATASE, 3-ISOPROPYLMALATE AND THREONINE SYNTHASE AS ANTIBIOTICS | ICORIA INC (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005050311-A1 | STABILIZED HIGH-SPEED EMULSIONS AND PHOTOTHERMOGRAPHIC MATERIALS | EASTMAN KODAK COMPANY (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050106514-A1 | Stabilized high-speed thermally developable emulsions and photothermographic materials | EASTMAN KODAK COMPANY | 2005-05-19 | — | — | US | claimed |
| EP-1461460-A2 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ASPARAGINE SYNTHASE, 5-AMINOLEVULINATE SYNTHASE, HISTIDINOL-PHOSPHATASE, 3-ISOPROPYLMALATE AND THREONINE SYNTHASE AS ANTIBIOTICS | Paradigm Genetics Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-6733963-B2 | FOR IDENTIFICATION OF FUNGICIDES WHICH AFFECT BIOSYNTHESIS OF L-LEUCINE; DRUG SCREENING | PARADIGM GENETICS, INC. | 2004-05-11 | — | — | US | claimed |
| US-20030143657-A1 | Methods for the identification of inhibitors of 3-isopropylmalate dehydratase as antibiotics | ICORIA, INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003050310-A2 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ASPARAGINE SYNTHASE, 5-AMINOLEVULINATE SYNTHASE, HISTIDINOL-PHOSPHATASE, 3-ISOPROPYLMALATE AND THREONINE SYNTHASE AS ANTIBIOTICS | PARADIGM GENETICS, INC. (US) | 2003-06-19 | — | — | WO | claimed |
| EP-0054223-A2 | Plasmid vectors for eukaryotic cells and method for selecting transfected eukaryotic cells | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-06-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606850-B2 | Synthesis of beta-hydroxyisovalerate and methods of use | CYP51A1, CYP4Z1, CYP2U1 | TSHR 1764/4885TP53 1633/4885SLC7A5 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.